[Effective concentration and dosage for cardiac glycosides].
The pharmacokinetic fundaments of the glycoside therapy with strophanthin, digoxin and digitoxin are described and compared with the traditional clinically oriented parameters total body stores, decay ratio and so on. Newly introduced is the parameter medium remaining duration in the circulation. A critical analysis of the hitherto cited values of the total body stores and the decay ratio established from the clinical effect shows that on the basis of pharmacokinetic calculations the corresponding values for digoxin and digotoxin need a great correction. The fully active quantity for digoxin lies between 0.5 and 0.8 mg and the subsiding share is 50%. The values for digitoxin lie at 0.9 mg and 9%. Furthermore the causes of the interindividual variability of the maintenance dose are discussed. According to the already existing international experiences an essential improvement of the therapy is possible, when the pharmacokinetically established effective constants are taken into consideration. Examinations of the inter- and intraindividual differences in the kinetics of the glycosides and the development of digoxin preparations with a high (i.e. constant) bioavailability may contribute to a further decrease of the frequency of toxic side-effects in future.
D001682:Biological Availability; D001702:Biopharmaceutics; D002301:Cardiac Glycosides / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism; D004074:Digitoxin / Q000494:pharmacology; D004077:Digoxin / Q000494:pharmacology; D006801:Humans; D013328:Strophanthins / Q000494:pharmacology; D013997:Time Factors
D002301:Cardiac Glycosides; D013328:Strophanthins; D004077:Digoxin; D004074:Digitoxin
Wirkkonstanten und Dosierung von Herzglykosiden.